Novartis CEO, as incoming PhRMA chair, outlines 3 priorities for pharma after IRA setback

After the pharma industry took a loss with the passage of the Inflation Reduction Act, companies are scouring for ways to blunt the new law’s effects. As the incoming chair of the powerful trade group PhRMA, Novartis CEO Vas Narasimhan has ideas about how the industry should respond.